单克隆抗体治疗IgG4相关疾病的研究进展

The progress of monoclonal antibodies in the treatment of IgG4 related disease

免疫球蛋白G4相关疾病(immunoglobulin-G4 related disease,IgG4-RD)是一类由免疫介导的慢性纤维炎性疾病,其特征是淋巴细胞、浆细胞浸润导致的纤维化和组织破坏。随着对IgG4-RD的病理生理学研究的深入及科学技术的发展,生物靶向治疗为有效控制疾病提供了可能性,同时也减少了药物带来的相关副作用。B细胞表面抗原CD20阻断剂利妥昔单抗是目前使用最广泛的靶向治疗药物,此外,奥贝利单抗、伊奈利珠单抗、埃罗妥珠单抗等多种单克隆抗体也在积极的进行临床试验。文章就单克隆抗体治疗IgG4-RD的研究进展进行综述,以期为IgG4-RD治疗提供依据。

Immunoglobulin-G4 related disease(IgG4-RD)is an immune mediated inflammatory disease characterized by fibrosis and tissue destruction attributed to the infiltration of lymphocyte and plasma cells.With the advancement in our understanding of IgG4-RD pathogenesis and the development of science and technology,targeted treatment approaches provides the possibility to effectively control the disease with fewer related side effects of drugs.At present,Rituximab,a B-cell surface anti-CD20 monoclonal antibody,is the most widely used targeted therapeutic agent.In addition,clinical trials concerning a variety of monoclonal antibodies including obelizumab,inelizumab and erottuzumab are actively undergoing.This review summarizes the research progress of monoclonal antibody therapy for IgG4-RD.